Market closed

TScan Therapeutics/$TCRX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About TScan Therapeutics

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Ticker

$TCRX
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Waltham, United States

Employees

194
Website
www.tscan.com

TCRX Metrics

BasicAdvanced
$149M
-
-$2.09
0.78
-

$149M

0.78

$9.69

$2.60

600K

9.563

9.46

37.74

39.442

-32.11%

-23.35%

-55.92%

14.988

0.61

0.61

-1.269

-44.71%

12.95%

5.02%

-33.64%

What the Analysts think about TCRX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for TScan Therapeutics stock.

TCRX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TCRX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

TCRX News

AllArticlesVideos
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

GlobeNewsWire·3 weeks ago
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

GlobeNewsWire·1 month ago
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TCRX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for TScan Therapeutics stock?

TScan Therapeutics (TCRX) has a market cap of $149M as of January 15, 2025.

What is the P/E ratio for TScan Therapeutics stock?

The price to earnings (P/E) ratio for TScan Therapeutics (TCRX) stock is 0 as of January 15, 2025.

Does TScan Therapeutics stock pay dividends?

No, TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next TScan Therapeutics dividend payment date?

TScan Therapeutics (TCRX) stock does not pay dividends to its shareholders.

What is the beta indicator for TScan Therapeutics?

TScan Therapeutics (TCRX) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.